Author Page for Shereen Suyin Ch'ng

Actions:

View:
Selected
Original List
All Versions Hide All Versions
All Abstracts Hide All Abstracts

(Rank)

Safety, Immunogenicity, and Efficacy of Recombinant COVID-19 Inhalation Vaccine (Adenovirus Type 5 Vector) as Second Booster Dose Against Emerging Variants of Concern (VOC) of SARS-CoV-2 to Prevent Breakthrough Infections: An Observer-Blinded, Randomised, Phase 3, Non-Inferiority Trial

Number of pages: 31 Posted: 18 Mar 2024

Institute for Clinical Research, CanSino Biologics Inc., Hospital Kuala Lumpur, Selayang Hospital, CanSino Biologics Inc., CanSino Biologics Inc., Institute for Clinical Research, Academy of Military Medical Sciences - Institute of Biotechnology, Hospital Kuala Lumpur, Selayang Hospital, Institute for Clinical Research, Hospital Kuala Lumpur, CanSino Biologics Inc., University of Malaya (UM), Academy of Military Medical Sciences - Institute of Biotechnology, Academy of Military Medical Sciences - Institute of Biotechnology, CanSino Biologics Inc., CanSino Biologics Inc., Clin Research Private Enterprise, CanSino Biologics Inc., Institute for Clinical Research and Independent

Downloads 103 (567,414)

Shereen Suyin Ch'ng

Selayang Hospital

1

103

0

Scholarly Papers (1)

Safety, Immunogenicity, and Efficacy of Recombinant COVID-19 Inhalation Vaccine (Adenovirus Type 5 Vector) as Second Booster Dose Against Emerging Variants of Concern (VOC) of SARS-CoV-2 to Prevent Breakthrough Infections: An Observer-Blinded, Randomised, Phase 3, Non-Inferiority Trial

Abstract: